Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CRISPR-Cas9 engineered anti-CD19 CAR T cells CTX110

A preparation of human allogeneic T lymphocytes transduced with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to eliminate endogenous TCR, with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-CD19 CAR T-cells CTX110 recognize and bind to CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. Removal of endogenous TCR reduces the risk of graft-versus-host disease (GvHD). CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Synonym:allogeneic anti-CD19 CAR CRISPR-edited T cells CTX110
allogeneic anti-CD19 CAR-T cells CTX110
allogeneic CRISPR-Cas9 gene-edited CD19-directed CAR T cells CTX110
allogeneic CRISPR-Cas9-engineered anti-CD19 CAR T cells CTX110
Code name:CTX 110
CTX-110
CTX101
CTX110
Search NCI's Drug Dictionary